SCHEMBL289401

SCHEMBL289401

CC(=O)c1sc(Br)nc1C

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXFP1 Q9HBX9 3/20 0.49
CYP1A2 P05177 1/20 0.49
GAA P10253 1/20 0.49
CYP2C9 P11712 1/20 0.49
ALDH1A1 P00352 7/20 0.47
SMN1; SMN2 Q16637 5/20 0.47
RAB9A P51151 5/20 0.47
NPC1 O15118 5/20 0.46
KMT2A Q03164 5/20 0.46
PKM P14618 1/20 0.46
HPGD P15428 1/20 0.46
MEN1 O00255 2/20 0.44
MAPT P10636 2/20 0.44
KDM4E B2RXH2 1/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
DHODH Q02127 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL241856 0.82 ALDH1A1 (0.61) GAAALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL13165457 0.82 RXFP1 (0.49) RXFP1CYP1A2GAACYP2C9ALDH1A1
SCHEMBL299157 0.80 LMNA (0.45) CYP1A2GAAALDH1A1SMN1; SMN2NPC1
SCHEMBL18482858 0.80 ALDH1A1 (0.40) RXFP1CYP1A2GAACYP2C9ALDH1A1
SCHEMBL1900249 0.80 ALDH1A1 (0.44) GAAALDH1A1SMN1; SMN2RAB9ANPC1
SCHEMBL211358 0.79 RXFP1 (0.50) RXFP1CYP1A2GAACYP2C9ALDH1A1
Bromide SCHEMBL6121613 0.77 SMN1; SMN2 (0.49) RXFP1CYP1A2GAACYP2C9ALDH1A1
SCHEMBL10672138 0.77 ALDH1A1 (0.49) RXFP1CYP1A2GAACYP2C9ALDH1A1
SCHEMBL560326 0.77 RAB9A (0.51) RXFP1GAAALDH1A1SMN1; SMN2RAB9A
SCHEMBL16434197 0.77 ALDH1A1 (0.54) RXFP1ALDH1A1SMN1; SMN2KMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116669744-A Nrf2 activating compounds 千寿制药株式会社 2023-08-29 CN disclosed
EP-3405477-B1 INHIBITORS OF TRANSGLUTAMINASES ZEDIRA GMBH (DE) 2023-06-07 EP disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
WO-2022145459-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2022-07-07 WO disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed
CN-114080389-A Nrf2 activating compound 千寿制药株式会社 2022-02-22 CN disclosed
WO-2021002473-A1 NRF2-ACTIVATING COMPOUND 千寿製薬株式会社 2021-01-07 WO disclosed
US-10543223-B2 Mannose derivatives useful for treating pathologies associated with adherent E. coli ENTEROME (FR) 2020-01-28 US disclosed
US-10543223-B2 Mannose derivatives useful for treating pathologies associated with adherent E. coli ENTEROME (FR) 2020-01-28 US disclosed
EP-2726481-B1 INSECTICIDALLY ACTIVE PYRIDYL-THIAZOLE AND PYRIDYL-THIADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2015-01-21 EP disclosed
US-8895552-B2 Cyclic amide derivative SUMITOMO DAINIPPON PHARMA CO., LTD. (JP) 2014-11-25 US disclosed
US-20140283218-A1 INSECTICIDALLY ACTIVE PYRIDYL-THIAZOLE AND PYRIDYL-THIADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2014-09-18 US disclosed
EP-2726481-A1 INSECTICIDALLY ACTIVE PYRIDYL-THIAZOLE AND PYRIDYL-THIADIAZOLE DERIVATIVES Syngenta Participations AG (CH) 2014-05-07 EP disclosed
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2013-08-22 US disclosed
WO-2013000931-A1 INSECTICIDALLY ACTIVE PYRIDYL-THIAZOLE AND PYRIDYL-THIADIAZOLE DERIVATIVES SYNGENTA PARTICIPATIONS AG (CH) 2013-01-03 WO disclosed
EP-2540718-A1 Novel insecticides Syngenta Participations AG. (CH) 2013-01-02 EP disclosed
EP-2427447-A2 SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION Pike Pharma GmbH (CH) 2012-03-14 EP disclosed
WO-2010128163-A2 SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION PIKE PHARMA GMBH (CH) 2010-11-11 WO disclosed
WO-2010128163-A2 SMALL MOLECULE INHIBITORS OF INFLUENZA A AND B VIRUS AND RESPIRATORY SYNCYTIAL VIRUS REPLICATION PIKE PHARMA GMBH (CH) 2010-11-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024995-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 RXFP1 570/4885CYP1A2 536/4885GAA 4396/4885
US-20140283218-A1 INSECTICIDALLY ACTIVE PYRIDYL-THIAZOLE AND PYRIDYL-THIADIAZOLE DERIVATIVES DDT, CYP4B1, CYP2E1 RXFP1 3775/4885CYP1A2 21/4885GAA 3771/4885
US-10543223-B2 Mannose derivatives useful for treating pathologies associated with adherent E. coli FPR3, CCR3, RXFP3 RXFP1 83/4885CYP1A2 2254/4885GAA 3777/4885
US-20130217692-A1 CYCLIC AMIDE DERIVATIVE HDAC10, H1-10, H1-0 RXFP1 496/4885CYP1A2 75/4885GAA 4354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.